Clinical Trials Directory

Trials / Completed

CompletedNCT06265077

Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients

Efficacy and Safety of Loratadine and Famotidine Combination on Preventing Filgrastim-Induced Bone Pain in Breast Cancer Patients

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
58 (actual)
Sponsor
Noha Mansour · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

No randomized controlled trial evaluated the safety and efficacy of double blockade on G-CSF induced bone pain. Therefore, this study aims to evaluate the efficacy and safety of double blockade on the incidence and severity of G-CSF induced bone pain.

Conditions

Interventions

TypeNameDescription
DRUGPlaceboPlacebo
DRUGfamotidine and loratadinefamotidine 20 mg once daily and loratadine 10 mg once daily

Timeline

Start date
2024-02-01
Primary completion
2024-10-17
Completion
2024-10-17
First posted
2024-02-20
Last updated
2024-12-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06265077. Inclusion in this directory is not an endorsement.

Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients (NCT06265077) · Clinical Trials Directory